Lightspeed Venture Partners founding partner Ravi Mhatre explains why he's particularly excited about opportunities in the life sciences over the next two decades. He envisions a future in which computing and data science unlock innumerable genetic puzzles, dramatically accelerating diagnosis, treatment and drug development.

Transcript

- We are just getting to the point where, again, because of things like, you know, DNA sequencing becoming a cheap way to digitize the life science industry where that industry is going to be able to participate in Moore's Law's curve of basically computing and problem solving getting better by a factor of 10 every probably 18 to 24 months. And so, I think, you know, everything from how drug development happens to, you know, how you would diagnose a disease and understand how to be treated, these are things where, you know, science has provided meaningful leaps forward over the last 60 or 70 years, but I think in the next 10 or 20, we're gonna see even more unlocks than we probably have cumulatively in the last 60 or 70. And it really does relate to being able to... I mean, the human body is a very incredibly complex analog machine. You know, we have 4.3 billion DNA pairs in our body, and the ability to use computing and data to understand each human individually and understand from what we know how medicine and how science should be applied, you know, people have called it personalized medicine. That's part of it. You know, from everything we've seen, I think that's an area where the gains that are gonna be made are gonna be just stunning...